Aurobindo Pharma shares: In the March quarter, Aurobindo Pharma posted a consolidated revenue of ₹8,382.1 crore, marking an 11% increase compared to the same period last year, aligning closely with market expectations. This growth was primarily fueled by a 13.5% year-on-year rise in US formulation sales and a 17.2% increase in European formulation sales.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets